Shots:
- Eli Lilly reported the P-I (AJX-101) trial, assessing AJ1-11095 (25, 50, 75, 100, & 125mg, QD) in 23 pts with myelofibrosis who have been failed by a type I JAK2 inhibitor, at EHA 2026
- AJ1-11095 achieved a 70% SVR35 & 70% TSS50 rate at Wk. 12, with driver mutation VAF reductions observed in 21 pts; among those who reached 24wks. (n=17), 59% achieved ≥20% & 35% achieved ≥50% VAF reductions across JAK2, MPL, & CALR mutations
- AJ1-11095 is being evaluated in an expansion cohort for 2L myelofibrosis, with planned studies in high-risk polycythemia vera & JAK2 inhibitor-naïve myelofibrosis pts
Ref: PRnewswire | Image: Eli Lilly | Press Release
Related News: Eli Lilly Receives the US FDA Approval for Ebglyss as a Q8W Maintenance Therapy for Atopic Dermatitis
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
